Esperion Therapeutics, Inc.

1 marketed · 1 in Phase 3

Quick facts

Marketed products

Ezetimibe 10mg

Phase 3 pipeline

ETC-1002 · Cardiovascular
ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels.

Phase 1 pipeline

[14C-ETC-1002]

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: